The Trial Design Is the Safety Argument

Diazgranados and colleagues, and later Zarate and colleagues, studied ketamine in treatment-resistant bipolar depression and found rapid antidepressant effect. Both were add-on trials: every participant was already on therapeutic lithium or valproate. Nobody has demonstrated that ketamine is safe as monotherapy in bipolar depression, because that study was not run. Any provider treating bipolar depression with ketamine and no mood stabilizer has left the evidence behind.

• Both landmark trials were add-on designs, not monotherapy
• Participants were on therapeutic-level lithium or valproate throughout
• Rapid antidepressant effect was observed, including on suicidal ideation
• Monotherapy safety in bipolar depression has not been established
• Requiring a mood stabilizer follows the evidence rather than exceeding it

Mania and Mood Switch, Said Directly

Any antidepressant-class intervention in bipolar disorder carries a risk of switching a patient into hypomania or mania. Ketamine is fast, which means a switch can appear quickly. This is manageable with an adequate mood stabilizer, a psychiatrist involved, and monitoring that is planned rather than improvised, and it is unmanageable without those things.

• Mood switch is a real risk for every antidepressant-class treatment in bipolar
• A therapeutic mood stabilizer is the principal mitigation
• Rapid-cycling presentations need particular caution
• Your support person is briefed on what a switch looks like
• Emerging hypomania stops the course rather than adjusting the dose

Undiagnosed Bipolar Is the Bigger Problem

The patients most at risk are not the ones who know they have bipolar disorder. They are the ones carrying a treatment-resistant depression label who have never been screened for bipolarity. Antidepressant non-response is itself a signal for unrecognized bipolar 2, and it is a common reason a depression that will not lift does not lift. This is why MDQ screening runs for everyone here, not only for people who mention bipolar.

• Bipolar 2 is frequently mislabeled as treatment-resistant unipolar depression
• Repeated antidepressant failure is a recognized signal for bipolarity
• Hypomania is under-reported because it rarely feels like a problem at the time
• MDQ screening is run for every patient regardless of stated history
• A positive screen changes the plan and may mean declining treatment

Medication Interactions That Matter Here

Bipolar regimens are complex and several components change how a ketamine course runs. Lamotrigine is the most interesting: it reduces glutamate release, which is the system ketamine acts on, and there is evidence it may blunt the response. That is a discussion with your psychiatrist rather than a reason to change anything unilaterally.

• Lamotrigine may reduce ketamine response through glutamatergic action
• Lithium requires stable levels and is monitored on its usual schedule
• Antipsychotics such as quetiapine and aripiprazole add sedation
• Benzodiazepines may blunt response, as in other indications
• No bipolar medication is adjusted without your psychiatrist

Candidacy

This is the most restrictive candidacy list on the site, and appropriately so. Telehealth suits stable bipolar depression under existing psychiatric care. It does not suit unstable bipolar illness, which needs a level of monitoring a home program cannot provide.

• Adults 18 and over with a confirmed bipolar diagnosis from a psychiatrist
• Established on a therapeutic mood stabilizer, not starting one now
• Currently in a depressive phase, with no recent hypomanic or manic episode
• An existing psychiatrist who will co-manage and is told about this treatment
• No active psychosis, substance use disorder, or suicidal planning
• A sober support person present for every session